Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 755


Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole.

Oishi M, Takano Y, Torita Y, Malhotra B, Chiba K.

Drug Metab Pharmacokinet. 2018 Feb;33(1):90-95. doi: 10.1016/j.dmpk.2017.11.005. Epub 2017 Nov 15.


Comparison of Oral Voriconazole Versus Oral Ketoconazole as an Adjunct to Topical Natamycin in Severe Fungal Keratitis: A Randomized Controlled Trial.

Sharma N, Singhal D, Maharana PK, Sinha R, Agarwal T, Upadhyay AD, Velpandian T, Satpathy G, Titiyal JS.

Cornea. 2017 Dec;36(12):1521-1527. doi: 10.1097/ICO.0000000000001365.


Oral Candida in Patients with Fixed Orthodontic Appliance: In Vitro Combination Therapy.

Alhamadi W, Al-Saigh RJ, Al-Dabagh NN, Al-Humadi HW.

Biomed Res Int. 2017;2017:1802875. doi: 10.1155/2017/1802875. Epub 2017 Jun 8.


Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.

Gidal BE, Maganti R, Laurenza A, Yang H, Verbel DA, Schuck E, Ferry J.

Epilepsy Res. 2017 Aug;134:41-48. doi: 10.1016/j.eplepsyres.2017.04.018. Epub 2017 Apr 26.


Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.

Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA.

Br J Clin Pharmacol. 2017 Oct;83(10):2242-2248. doi: 10.1111/bcp.13329. Epub 2017 Jun 19.


A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.

Einolf HJ, Zhou J, Won C, Wang L, Rebello S.

Drug Metab Dispos. 2017 Apr;45(4):361-374. doi: 10.1124/dmd.116.073585. Epub 2017 Jan 25.


Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.

Freise KJ, Shebley M, Salem AH.

J Clin Pharmacol. 2017 Jun;57(6):796-804. doi: 10.1002/jcph.858. Epub 2017 Jan 4.


Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL.

Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18.


Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.

Fowler S, Guerini E, Qiu N, Cleary Y, Parrott N, Greig G, Mallalieu NL.

J Pharmacol Exp Ther. 2017 Jan;360(1):164-173. Epub 2016 Nov 7.


In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.

Johansson S, Löfberg B, Aunes M, Lunde H, Frison L, Edvardsson N, Cullberg M.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):364-73. doi: 10.1002/cpdd.250. Epub 2016 Mar 23.


Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.

Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K.

Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600. doi: 10.1111/bcp.13092. Epub 2016 Sep 23.


A highly sensitive LC-MS/MS method for determination of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical administration.

Wang K, Wu Y, Chi Z, Shu C, Li L, Wei J, Tao L, Ma P, Ding L.

J Pharm Biomed Anal. 2016 Sep 5;128:504-509. doi: 10.1016/j.jpba.2016.06.025. Epub 2016 Jun 19.


Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.

de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M.

Clin Pharmacol Ther. 2016 Nov;100(5):548-557. doi: 10.1002/cpt.419. Epub 2016 Aug 27.


Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.

Shin KH, Ahn LY, Choi MH, Moon JY, Lee J, Jang IJ, Yu KS, Cho JY.

AAPS J. 2016 Sep;18(5):1254-61. doi: 10.1208/s12248-016-9941-y. Epub 2016 Jun 17.


Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.

Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, Lasseter K, Pearlman H, Rammelsberg D, Schmitt-Hoffmann A, Yamazaki T, Desai A.

Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53. doi: 10.1002/cpdd.285. Epub 2016 Jul 25.


Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Cotreau MM, Siebers NM, Miller J, Strahs AL, Slichenmyer W.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):137-42. doi: 10.1002/cpdd.145. Epub 2014 Oct 1.


Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

Martin P, Gillen M, Millson D, Oliver S, Brealey C, Grossbard EB, Baluom M, Lau D, Sweeny D, Mant T, Craven K.

Drugs R D. 2016 Mar;16(1):81-92. doi: 10.1007/s40268-015-0118-4.


Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol.

Bui K, Zhou D, Sostek M, She F, Al-Huniti N.

J Clin Pharmacol. 2016 Aug;56(8):1019-27. doi: 10.1002/jcph.693. Epub 2016 Feb 24.


Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.

Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM.

Antimicrob Agents Chemother. 2015 Oct 12;60(1):105-14. doi: 10.1128/AAC.01778-15. Print 2016 Jan.

Supplemental Content

Loading ...
Support Center